Literature DB >> 12669768

The type of isoniazid acetylation in tuberculosis patients treated at National Tuberculosis and Lung Diseases Research Institute.

Ewa Augustynowicz-Kopeć1, Zofia Zwolska.   

Abstract

The research has dealt with types of acetylation in 237 TB patients treated by standard course of chemotherapy with a 300 mg dose of INH at the National Tuberculosis and Lung Diseases Research Institute in Warsaw (NTLDRI). Blood samples were taken before (time 0) and 1, 3, 6 and 24 h after drug administration. Plasma concentrations of isoniazid were determined with biological methods. Two indicators of acetylation rate--I3 and C6 have been used to determine the acetylation type. Majority of the treated patients (68.8%) have shown fast type of INH acetylation. After similar dose of isoniazid different profile of absorption and excretion of the drug and significant differences (p < 0.01) in INH concentrations, acetylation rate and bioavailability between 163 fast and 74 slow acetylators have been observed. In plasma of 38.6% fast acetylators drug concentration 3h after ingestion of the dose did not achieve the concentration of 1 mcg/ml. In plasma of 29.7% slow acetylators, concentrations of INH 6h after ingestion were higher than 2 mcg/ml.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12669768

Source DB:  PubMed          Journal:  Acta Pol Pharm        ISSN: 0001-6837            Impact factor:   0.330


  2 in total

1.  Preparation and antitubercular activities in vitro and in vivo of novel Schiff bases of isoniazid.

Authors:  Michael J Hearn; Michael H Cynamon; Michaeline F Chen; Rebecca Coppins; Jessica Davis; Helen Joo-On Kang; Abigail Noble; Becky Tu-Sekine; Marianne S Terrot; Daniella Trombino; Minh Thai; Eleanor R Webster; Rebecca Wilson
Journal:  Eur J Med Chem       Date:  2009-05-21       Impact factor: 6.514

2.  Correlation of N-acetyltransferase 2 genotype with isoniazid acetylation in Polish tuberculosis patients.

Authors:  Anna Zabost; Sylwia Brzezińska; Monika Kozińska; Maria Błachnio; Jacek Jagodziński; Zofia Zwolska; Ewa Augustynowicz-Kopeć
Journal:  Biomed Res Int       Date:  2013-12-07       Impact factor: 3.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.